Taiyen Biotech Co., Ltd. (TPE:1737)
Taiwan · Delayed Price · Currency is TWD 32.10
-0.10 (-0.31%)
Aug 19, 2026, 1:30 PM CST
Taiyen Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,190 | 3,308 | 3,238 | 3,409 | 3,614 | 4,096 | |
Revenue Growth | -3.27% | 2.15% | -5.01% | -5.67% | -11.77% | 30.84% |
Cost of Revenue | 1,931 | 1,965 | 1,917 | 2,151 | 2,337 | 2,722 |
Gross Profit | 1,257 | 1,341 | 1,321 | 1,257 | 1,277 | 1,373 |
Selling, General & Admin | 809.15 | 821.75 | 835.39 | 801.98 | 770.92 | 786.46 |
Research & Development | 53.87 | 54.78 | 54.71 | 60.5 | 60.64 | 57.6 |
Operating Expenses | 831.58 | 866.87 | 966.37 | 936.04 | 831.56 | 844.06 |
Operating Income | 425.06 | 474.19 | 354.54 | 321.44 | 445.05 | 529.18 |
Interest Expense | -3 | -3.72 | -6.34 | -3.35 | -4.52 | -5.94 |
Interest & Investment Income | 20.8 | 26.35 | 37.93 | 35.93 | 17.88 | 10.66 |
Currency Exchange Gain (Loss) | 17.27 | -16.74 | 38.54 | -5.67 | 58.69 | -20.59 |
Other Non Operating Income (Expenses) | 29.03 | 29.31 | 2.99 | -21.26 | 20.65 | 1.93 |
EBT Excluding Unusual Items | 489.16 | 509.38 | 427.66 | 327.1 | 537.74 | 515.23 |
Gain (Loss) on Sale of Investments | 13.87 | 7.61 | 12.85 | 7.43 | -0.36 | -0.54 |
Gain (Loss) on Sale of Assets | -0.52 | -0.48 | -1.04 | -1.28 | -1.28 | -1.24 |
Other Unusual Items | -22.24 | -22.54 | -6.44 | -4.13 | -5.52 | -3.54 |
Pretax Income | 480.27 | 493.97 | 433.03 | 329.12 | 530.59 | 509.92 |
Income Tax Expense | 90.75 | 100.28 | 115.58 | 111.82 | 103.07 | 97.76 |
Earnings From Continuing Operations | 389.53 | 393.69 | 317.45 | 217.3 | 427.52 | 412.16 |
Minority Interest in Earnings | - | 6.18 | 54.07 | 83.09 | -0.81 | -18.94 |
Net Income | 389.53 | 399.87 | 371.52 | 300.39 | 426.7 | 393.23 |
Net Income to Common | 389.53 | 399.87 | 371.52 | 300.39 | 426.7 | 393.23 |
Net Income Growth | 10.45% | 7.63% | 23.68% | -29.60% | 8.51% | 7.71% |
Shares Outstanding (Basic) | 200 | 200 | 200 | 200 | 200 | 200 |
Shares Outstanding (Diluted) | 201 | 201 | 201 | 200 | 201 | 201 |
Shares Change | 0.02% | 0.04% | 0.06% | -0.08% | 0.05% | - |
EPS (Basic) | 1.95 | 2.00 | 1.86 | 1.50 | 2.13 | 1.97 |
EPS (Diluted) | 1.94 | 1.99 | 1.85 | 1.50 | 2.13 | 1.96 |
EPS Growth | 10.85% | 7.57% | 23.33% | -29.58% | 8.67% | 7.69% |
Free Cash Flow | 249.96 | 131.89 | 352.51 | 112.89 | 334.58 | 211.29 |
Free Cash Flow Per Share | 1.25 | 0.66 | 1.76 | 0.56 | 1.67 | 1.05 |
Dividend Per Share | 1.400 | 1.400 | 1.300 | 1.200 | 1.500 | 1.500 |
Dividend Growth | 7.69% | 7.69% | 8.33% | -20.00% | 0% | 11.11% |
Gross Margin | 39.40% | 40.54% | 40.79% | 36.89% | 35.33% | 33.53% |
Operating Margin | 13.33% | 14.34% | 10.95% | 9.43% | 12.32% | 12.92% |
Profit Margin | 12.21% | 12.09% | 11.47% | 8.81% | 11.81% | 9.60% |
Free Cash Flow Margin | 7.84% | 3.99% | 10.89% | 3.31% | 9.26% | 5.16% |
EBITDA | 673.75 | 710.17 | 561.57 | 508.88 | 628.74 | 707.81 |
EBITDA Margin | 21.12% | 21.47% | 17.34% | 14.93% | 17.40% | 17.28% |
D&A For EBITDA | 248.69 | 235.98 | 207.03 | 187.44 | 183.69 | 178.64 |
EBIT | 425.06 | 474.19 | 354.54 | 321.44 | 445.05 | 529.18 |
EBIT Margin | 13.33% | 14.34% | 10.95% | 9.43% | 12.32% | 12.92% |
Effective Tax Rate | 18.89% | 20.30% | 26.69% | 33.98% | 19.43% | 19.17% |